
Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)
Recursion acquires two AI-based drug discovery companies in $87.5M deal
AI drug developer Recursion Pharmaceuticals has brought two more AI-focused companies with their own discovery platforms under its wing in an acquisition worth $87.5 million, the company announced today.
Recursion is buying both companies, Cyclica and Valence, mostly in equity. The deals come as insiders predict a surge in biotech M&A — with smaller players, not just Big Pharma, ready to jump on tuck-in acquisitions of even smaller companies.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters